We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

99 hedge funds and large institutions have $36.1M invested in Protalix BioTherapeutics in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 28 increasing their positions, 20 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 9

70% more call options, than puts

Call options by funds: $651K | Put options by funds: $383K

40% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 20

35% more capital invested

Capital invested by funds: $26.8M → $36.1M (+$9.28M)

19% more funds holding

Funds holding: 83 → 99 (+16)

2.13% more ownership

Funds ownership: 18.53% → 20.66% (+2.1%)

Holders
99
Holders Change
+16
Holders Change %
+19.28%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
28
Reduced
20
Closed
9
Calls
$651K
Puts
$383K
Net Calls
+$268K
Net Calls Change
+$287K

Top Buyers

1
MCO
MAK Capital One
New York
+$8.79M
2
PFS
Prospera Financial Services
Texas
+$1.04M
3
State Street
State Street
Massachusetts
+$962K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$665K
5
Morgan Stanley
Morgan Stanley
New York
+$421K

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$5.31M
2
Citadel Advisors
Citadel Advisors
Florida
-$788K
3
Jane Street
Jane Street
New York
-$676K
4
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$378K
5
Barclays
Barclays
United Kingdom
-$243K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$7.85M -$74.8K -30,144 -0.8%
MCO
2
MAK Capital One
New York
$7.69M +$8.79M +3,544,139 New
Renaissance Technologies
3
Renaissance Technologies
New York
$2.66M -$95.5K -38,500 -3%
State Street
4
State Street
Massachusetts
$2.11M +$962K +387,554 +66%
Northern Trust
5
Northern Trust
Illinois
$1.92M +$49K +19,740 +2%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$1.88M +$87.5K +35,244 +4%
SWP
7
Stratos Wealth Partners
Ohio
$1.08M – – –
VPM
8
Vanguard Portfolio Management
Pennsylvania
$938K +$1.07M +432,485 New
PFS
9
Prospera Financial Services
Texas
$908K +$1.04M +418,570 New
OM
10
Opaleye Management
Massachusetts
$738K -$5.31M -2,138,176 -86%
Morgan Stanley
11
Morgan Stanley
New York
$655K +$421K +169,806 +129%
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$644K +$665K +268,099 +933%
UBS Group
13
UBS Group
Switzerland
$576K +$7.48K +3,015 +1%
Goldman Sachs
14
Goldman Sachs
New York
$545K -$28.4K -11,464 -4%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$476K +$20.9K +8,440 +4%
Connor, Clark & Lunn Investment Management (CC&L)
16
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$450K -$61.6K -24,818 -11%
RRA
17
Round Rock Advisors
Connecticut
$417K +$91.8K +36,978 +24%
BCM
18
Bridgeway Capital Management
Texas
$410K – – –
ECM
19
Evergreen Capital Management
Washington
$372K – – –
Charles Schwab
20
Charles Schwab
California
$346K -$39.1K -15,759 -9%
DC
21
Diametric Capital
Massachusetts
$270K -$36.6K -14,734 -11%
N
22
Nuveen
North Carolina
$196K – – –
Lazard Asset Management
23
Lazard Asset Management
New York
$188K +$37.8K +15,224 +21%
Bank of America
24
Bank of America
North Carolina
$172K +$81.2K +32,727 +71%
Deutsche Bank
25
Deutsche Bank
Germany
$163K +$184K +74,139 +8,763%
1
2 3 4 5

PLX Hedge Fund Activity: Q1 2026 in Review

99 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2026, worth a combined $36.1M — up 35% from $26.8M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new PLX positions and 9 closed out — a net gain of 18 holders — while 28 added to existing stakes and 20 trimmed.

The largest buyer was MAK Capital One, opening a new position worth an estimated $8.79M. The largest seller was Opaleye Management, cutting an estimated $5.31M.

  • 99 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2026, up from 83 in Q4 2025.
  • Funds reported $36.1M of Protalix BioTherapeutics stock for Q1 2026, up 35% quarter-over-quarter.
  • 27 funds opened new Protalix BioTherapeutics positions in Q1 2026 and 9 closed out, a net change of +18 holders.
  • The largest Protalix BioTherapeutics buyer in Q1 2026 was MAK Capital One, an estimated $8.79M added.
  • The largest Protalix BioTherapeutics seller in Q1 2026 was Opaleye Management, an estimated $5.31M sold.

Based on aggregated 13F filings for Q1 2026.